NASDAQ NMS - GLOBAL MARKET · ACRV
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Acrivon Therapeutics Inc

Acrivon Therapeutics Inc

Biotechnology
$1.73
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
ACRV
Acrivon Therapeutics Inc
Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

75/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ACRV moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ACRV catalysts
About Acrivon Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2022
Employees
76
Country
US

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.73
Last session
Day high
$1.73
Last session
Day low
$1.73
Last session
Previous close
$1.73
52W high
$3.01
-42.52% from high
52W low
$1.23
28% of range
Market cap
$74M
EPS
$-2.0600
Beta
2.03
Shares out
42.8M
Avg volume
420.2K
VWAP
$1.73
Last session
Price history computed in-house
1W
+10.90%
1M
-11.73%
3M
-8.47%
1Y
+39.52%
YTD
-28.22%
SMA 50 $1.65 · above
SMA 200 $1.86 · below
52W position 28%

ACRV overview

Veridion Score
75
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ACRV.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ACRV Form 4 filings
Public disclosures

Congress activity in ACRV

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ACRV in the cached public ledger.

Federal contracts

ACRV contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ACRV in this window.
Lobbying spend

ACRV lobbying filings, year to date.

Registered lobbying filings matched to Acrivon Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ACRV in this window.
Loading news for ACRV
Analyst ratings
Sovereign unlock shows live analyst consensus for ACRV.
Options
Sovereign unlock shows live options positioning for ACRV.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.